High Yield Neurology Review for Step 2 CK & Shelf Exam

High Yield Neurology Review for Step 2 CK & Shelf Exam - Doctor High Yield, MD

1. Summary

This video provides a high-yield, 35-minute review of essential Neurology topics for 3rd-year medical students preparing for Step 2 CK and Neurology shelf exams. The focus is on covering the "big topics" to serve as an overview before broader internal medicine shelf studying or a final quick review. Mastering these concepts will indicate a strong grasp of the material.

2. Key Takeaways

* **Focus on High-Yield Concepts:** The video prioritizes the most frequently tested and crucial neurology topics.

* **Target Audience:** Designed for 3rd-year medical students preparing for shelf exams (especially Internal Medicine) and Step 2 CK.

* **Time Efficiency:** Aims to cover major neurology concepts in approximately 35 minutes.

* **Preparation Tool:** Useful as an initial overview or a last-minute review.

* **Confidence Indicator:** Familiarity with these concepts suggests a good level of preparedness.

3. Detailed Notes

This section will be structured by major neurological topics as presented in the video.

---

#### **I. Approach to Neurological Complaints**

* **Chief Complaint:** Understand the primary symptom and its characteristics (onset, duration, severity, associated symptoms, relieving/exacerbating factors).

* **History of Present Illness (HPI):** Detailed exploration of the chief complaint.

* **Past Medical History (PMH):** Relevant past neurological conditions, vascular risk factors, autoimmune diseases, etc.

* **Medications:** Current medications and recent changes.

* **Family History:** Neurological disorders in the family.

* **Social History:** Lifestyle, substance use.

* **Review of Systems (ROS):** Systemic symptoms that could have neurological implications.

* **Neurological Exam:**

* **Mental Status:** Alertness, orientation, cognition, language.

* **Cranial Nerves:** I-XII.

* **Motor System:** Strength, tone, bulk, reflexes, coordination.

* **Sensory System:** Light touch, pain/temperature, vibration, proprioception.

* **Gait and Station:** Observe walking, balance.

* **Cerebellar Function:** Finger-to-nose, heel-to-shin.

* **Special Tests:** Romberg's, Babinski.

---

#### **II. Common Neurological Disorders**

**(A) Stroke (Cerebrovascular Accident - CVA)**

* **Definition:** Disruption of blood supply to the brain, causing neurological deficits.

* **Types:**

* **Ischemic Stroke:** Most common (~85%). Caused by a blockage (thrombus or embolus).

* **Thrombotic:** Atherosclerosis at the site of occlusion.

* **Embolic:** Dislodged clot from elsewhere (e.g., heart, carotid artery).

* **Hemorrhagic Stroke:** (~15%). Bleeding into the brain.

* **Intracerebral Hemorrhage (ICH):** Bleeding within the brain parenchyma.

* **Subarachnoid Hemorrhage (SAH):** Bleeding into the subarachnoid space.

* **Risk Factors:** Hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation, age, family history.

* **Clinical Manifestations:** Sudden onset of focal neurological deficits.

* **MCA (Middle Cerebral Artery):** Contralateral weakness/sensory loss (face/arm > leg), aphasia (dominant hemisphere), hemineglect (non-dominant hemisphere).

* **ACA (Anterior Cerebral Artery):** Contralateral weakness/sensory loss (leg > arm), behavioral changes.

* **PCA (Posterior Cerebral Artery):** Visual field deficits (hemianopia), visual hallucinations, sensory deficits.

* **Vertebrobasilar System:** Dizziness, vertigo, diplopia, dysarthria, ataxia, cranial nerve palsies, hemiparesis/hemiplegia.

* **Diagnosis:**

* **CT Scan (Non-contrast):** Initial imaging of choice to rule out hemorrhage.

* **CT Angiography (CTA) / MRI Angiography (MRA):** To visualize blood vessels and identify occlusions.

* **MRI Brain:** More sensitive for acute ischemic changes.

* **ECG/Echocardiogram:** To assess for cardiac sources of emboli.

* **Management:**

* **Ischemic Stroke:**

* **Thrombolysis (tPA):** If within the time window (usually 3-4.5 hours from symptom onset) and no contraindications.

* **Mechanical Thrombectomy:** For large vessel occlusions (LVOs) in eligible patients.

* **Antiplatelet Therapy:** Aspirin, clopidogrel.

* **Anticoagulation:** For cardioembolic strokes or specific indications.

* **Blood Pressure Management:** Lowering BP cautiously to avoid reducing perfusion.

* **Hemorrhagic Stroke:**

* **Blood Pressure Control:** Aggressive BP lowering.

* **Reversal of Anticoagulation:** If applicable.

* **Surgical Intervention:** For large hematomas, hydrocephalus, or cerebellar hemorrhages.

* **Secondary Prevention:** Risk factor modification (BP control, statins, diabetes management, smoking cessation, anticoagulation for AF).

**(B) Seizures and Epilepsy**

* **Definition:** A transient event due to abnormal, excessive, or synchronous neuronal activity in the brain.

* **Epilepsy:** A disorder characterized by recurrent, unprovoked seizures.

* **Classification of Seizures:**

* **Focal (Partial) Seizures:** Originate in one hemisphere.

* **Aware:** Person remains conscious.

* **Impaired Awareness:** Person's consciousness is affected.

* **Focal to Bilateral Tonic-Clonic:** Starts focal and then generalizes.

* **Generalized Seizures:** Originate in and involve both hemispheres from the outset.

* **Absence:** Brief lapses of awareness.

* **Tonic-Clonic:** Stiffening (tonic) followed by jerking (clonic).

* **Myoclonic:** Brief, shock-like jerks.

* **Atonic:** Sudden loss of muscle tone.

* **Causes of Seizures:**

* **Structural:** Brain tumors, stroke, trauma, malformations.

* **Genetic:** Idiopathic epilepsies.

* **Metabolic:** Hypoglycemia, hyponatremia, hepatic encephalopathy, drug withdrawal.

* **Infectious:** Meningitis, encephalitis.

* **Autoimmune:** Anti-NMDA receptor encephalitis.

* **Status Epilepticus:** A prolonged seizure or multiple seizures occurring without recovery of consciousness between them. Medical emergency.

* **Diagnosis:**

* **History and Physical Exam:** Crucial for diagnosis and classification.

* **EEG (Electroencephalogram):** To detect abnormal electrical activity.

* **MRI Brain:** To identify structural causes.

* **Blood Tests:** To rule out metabolic causes.

* **Management:**

* **Antiepileptic Drugs (AEDs):**

* **First-line for generalized tonic-clonic:** Levetiracetam, valproate, lamotrigine.

* **First-line for focal:** Levetiracetam, carbamazepine, phenytoin, lamotrigine.

* **First-line for absence:** Ethosuximide, valproate.

* **Status Epilepticus Management:** Benzodiazepines (lorazepam, diazepam) followed by longer-acting AEDs (fosphenytoin, valproate, levetiracetam).

* **Epilepsy Surgery/Devices:** For refractory epilepsy.

**(C) Parkinson's Disease (PD)**

* **Definition:** A progressive neurodegenerative disorder affecting the dopaminergic neurons in the substantia nigra.

* **Pathology:** Loss of dopaminergic neurons, leading to dopamine deficiency in the basal ganglia. Presence of Lewy bodies.

* **Clinical Triad (TRAP):**

* **T**remor: Resting tremor, "pill-rolling," often starts unilaterally.

* **R**igidity: Cogwheel rigidity, increased resistance to passive movement.

* **A**kinesia/Bradykinesia: Slowness of movement, difficulty initiating movement.

* **P**ostural Instability: Impaired balance and coordination, leading to falls (typically a later symptom).

* **Other Symptoms:** Masked facies, micrographia, hypophonia, stooped posture, shuffling gait, autonomic dysfunction (constipation, orthostatic hypotension), cognitive impairment, depression.

* **Diagnosis:** Primarily clinical, based on the presence of bradykinesia plus at least one of tremor or rigidity. Response to levodopa supports the diagnosis.

* **Management:**

* **Levodopa:** Most effective symptomatic treatment (converted to dopamine in the brain). Often combined with carbidopa to reduce peripheral side effects.

* **Dopamine Agonists:** Pramipexole, ropinirole.

* **MAO-B Inhibitors:** Selegiline, rasagiline.

* **COMT Inhibitors:** Entacapone (used adjunctively with levodopa).

* **Deep Brain Stimulation (DBS):** For selected patients with motor fluctuations or disabling dyskinesias.

* **Supportive Care:** Physical therapy, occupational therapy, speech therapy.

**(D) Alzheimer's Disease (AD)**

* **Definition:** The most common cause of dementia, characterized by progressive cognitive decline.

* **Pathology:** Accumulation of amyloid-beta plaques and neurofibrillary tangles (tau protein) in the brain.

* **Clinical Manifestations:**

* **Early Stages:** Memory loss (especially recent events), difficulty with word finding, impaired executive function.

* **Progressive Stages:** Worsening memory, disorientation, impaired judgment, personality changes, motor deficits, eventual loss of ability to perform daily activities.

* **Diagnosis:**

* **Clinical Evaluation:** History, cognitive assessments (MMSE, MoCA).

* **Exclusion of other causes of dementia:** Vascular dementia, Lewy body dementia, frontotemporal dementia, reversible causes (e.g., B12 deficiency, thyroid dysfunction).

* **Neuroimaging (MRI/CT):** To rule out other pathology and show brain atrophy (especially in hippocampus and medial temporal lobes).

* **Cerebrospinal Fluid (CSF) analysis:** May show low amyloid-beta and high tau.

* **PET scans:** Amyloid or tau PET scans can be used in select cases.

* **Management:**

* **Cholinesterase Inhibitors:** Donepezil, rivastigmine, galantamine (symptomatic treatment, may slow decline slightly).

* **NMDA Receptor Antagonist:** Memantine (for moderate to severe AD).

* **Disease-Modifying Therapies:** Newer treatments like Aducanumab and Lecanemab target amyloid-beta, but their use is complex and debated.

* **Supportive Care:** Managing behavioral symptoms, caregiver support.

**(E) Multiple Sclerosis (MS)**

* **Definition:** A chronic inflammatory demyelinating disease of the central nervous system (CNS).

* **Pathology:** Autoimmune attack on myelin sheaths and oligodendrocytes in the CNS, leading to plaques of demyelination.

* **Types:**

* **Relapsing-Remitting MS (RRMS):** Most common initially. Episodes of new or worsening neurological symptoms (relapses) followed by periods of recovery (remissions).

* **Secondary Progressive MS (SPMS):** Worsening disability over time, with or without relapses, after an initial RRMS course.

* **Primary Progressive MS (PPMS):** Gradual neurological deterioration from onset, without distinct relapses or remissions.

* **Clinical Manifestations:** Highly variable, depending on the location of lesions.

* **Sensory:** Numbness, tingling, paresthesias.

* **Motor:** Weakness, spasticity, gait disturbances.

* **Visual:** Optic neuritis (pain with eye movement, decreased vision, dyschromatopsia), diplopia.

* **Cerebellar:** Ataxia, dysmetria, tremor.

* **Brainstem:** Vertigo, dysarthria.

* **Bladder/Bowel Dysfunction:** Urgency, frequency, constipation.

* **Fatigue:** Very common and disabling.

* **Pain:** Neuropathic pain.

* **Cognitive Impairment:** Slowed processing speed, memory problems.

* **Lhermitte's Sign:** Electric shock-like sensation down the spine with neck flexion.

* **Diagnosis:**

* **Clinical History and Neurological Exam:** Evidence of lesions disseminated in space and time.

* **MRI Brain and Spinal Cord:** Essential for detecting demyelinating lesions (periventricular white matter, corpus callosum, infratentorial). Gadolinium enhancement indicates active inflammation.

* **Evoked Potentials:** Visual evoked potentials (VEPs) often show delayed latency.

* **CSF Analysis:** Oligoclonal bands and elevated IgG index are characteristic.

* **Management:**

* **Acute Relapse Treatment:** High-dose corticosteroids (IV methylprednisolone) to reduce inflammation and shorten relapse duration.

* **Disease-Modifying Therapies (DMTs):** Aim to reduce relapse frequency, severity, and disease progression. Options include interferons, glatiramer acetate, fingolimod, natalizumab, ocrelizumab, etc. Choice depends on disease activity, patient factors, and route of administration.

* **Symptomatic Management:** For fatigue, spasticity, pain, bladder dysfunction, etc.

**(F) Migraine**

* **Definition:** A primary headache disorder characterized by recurrent, moderate to severe, often unilateral headaches, typically associated with nausea, vomiting, and sensitivity to light and sound.

* **Types:**

* **Migraine without Aura:** Common. Pulsating headache, moderate to severe intensity, aggravated by physical activity, associated with nausea/vomiting or photophobia/phonophobia.

* **Migraine with Aura:** Includes transient neurological symptoms (aura) that usually precede or accompany the headache. Most common aura is visual (scintillating scotoma, flashing lights). Other auras: sensory (numbness), speech (dysarthria).

* **Phases of Migraine:**

* **Prodrome:** Subtle changes preceding the headache (mood changes, fatigue, food cravings).

* **Aura:** Neurological symptoms (if present).

* **Headache:** The main pain phase.

* **Postdrome:** Lingering fatigue, malaise after headache.

* **Diagnosis:** Primarily clinical, based on diagnostic criteria (e.g., ICHD-3).

* **Management:**

* **Acute Treatment (Abortive):**

* **Non-pharmacological:** Rest in a dark, quiet room.

* **Over-the-counter (OTC) analgesics:** NSAIDs, acetaminophen.

* **Triptans:** Serotonin 5-HT1B/1D receptor agonists (sumatriptan, rizatriptan).

* **Ditans:** Lasmiditan (serotonin 5-HT1F receptor agonist).

* **Gepants:** CGRP receptor antagonists (ubrogepant, rimegepant).

* **Anti-emetics:** Metoclopramide, prochlorperazine.

* **Preventive Treatment (Prophylactic):** For frequent or disabling migraines.

* **Beta-blockers:** Propranolol, metoprolol.

* **Anticonvulsants:** Topiramate, valproate.

* **Calcium channel blockers:** Verapamil (less common).

* **Antidepressants:** Amitriptyline, venlafaxine.

* **Monoclonal antibodies targeting CGRP:** Erenumab, fremanezumab, galcanezumab, eptinezumab.

* **Botulinum toxin A (Botox):** For chronic migraine.

**(G) Transient Ischemic Attack (TIA)**

* **Definition:** A temporary episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, *without* acute infarction. Symptoms resolve completely.

* **Clinical Presentation:** Same as stroke symptoms but transient.

* **ABCD2 Score:** Used to assess risk of stroke after a TIA (Age, Blood pressure, Clinical features, Duration of symptoms, Diabetes).

* **Management:**

* **Urgent Evaluation:** Within 24-72 hours to identify underlying cause.

* **Risk Factor Modification:** Similar to stroke prevention (BP control, statins, antiplatelets).

* **Antiplatelet Therapy:** Aspirin or clopidogrel.

* **Anticoagulation:** If cardioembolic source identified.

* **Carotid Endarterectomy/Stenting:** For significant carotid stenosis.

* **Significance:** A TIA is a warning sign of impending stroke.

---

#### **III. Neuroanatomy & Localization (Brief Mention)**

* **Motor Cortex:** Controls voluntary movement.

* **Sensory Cortex:** Processes sensory information.

* **Cerebellum:** Coordination, balance, fine motor control.

* **Basal Ganglia:** Motor control, reward, habit formation.

* **Brainstem:** Vital functions (breathing, heart rate), cranial nerve nuclei, tracts.

* **Spinal Cord:** Motor and sensory pathways to and from the body.

* **Localization:** Understanding the specific neurological deficit helps pinpoint the affected area of the nervous system. For example, hemiparesis with aphasia points to the dominant hemisphere's MCA territory.

---

#### **IV. Red Flags in Neurology**

* **Sudden onset severe headache ("thunderclap"):** Subarachnoid hemorrhage.

* **New onset seizure in an adult:** Rule out structural lesion, bleed, infection.

* **Progressive neurological deficit:** Suggests tumor, chronic inflammatory process, or degenerative disease.

* **Focal neurological deficits:** Points to a specific lesion location.

* **Altered mental status with fever and neck stiffness:** Meningitis/encephalitis.

* **Unexplained gait disturbance:** Can be due to stroke, PD, spinal cord issues, or metabolic problems.

---

This structured note aims to capture the essential information presented in the Doctor High Yield video. Remember that this is a review, and further in-depth study of each topic is recommended.